Diabetes Treatment Devices Market Report 2025

The diabetes treatment devices market size has grown strongly in recent years. It will grow from $11.61 billion in 2024 to $12.34 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to several key factors, including the rising prevalence of diabetes, greater awareness about effective diabetes management, a growing adoption of insulin delivery devices, increased healthcare expenditure in developing countries, and the expanding availability of advanced glucose monitoring systems.

The diabetes treatment devices market size is expected to see strong growth in the next few years. It will grow to $15.61 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth projected for the forecast period can be attributed to several factors, including a rising demand for wearable and non-invasive monitoring devices, an increasing focus on personalized diabetes care, greater adoption of digital health platforms and apps, a growing need for remote diabetes management solutions, and expanding government initiatives supporting diabetes control programs. Key trends to watch during this period include advancements in continuous glucose monitoring technology, the development of advanced insulin delivery systems integrated with artificial intelligence, the rise of smart wearable diabetes devices, innovations in non-invasive blood sugar monitoring, and the integration of voice assistants into device operations.

The rising obesity rates are anticipated to accelerate the growth of the diabetes treatment devices market due to the increasing demand for solutions to manage diabetes. Obesity is determined by the percentage of individuals with a body mass index (BMI) classified as obese. The surge in obesity is mainly driven by poor dietary habits rich in calories, sugars, and fats, leading to excessive weight gain when not counterbalanced with physical activity. Diabetes treatment devices help manage blood sugar levels, which in turn promotes healthier lifestyle choices and assists in weight management. For instance, in September 2023, the Centers for Disease Control and Prevention (CDC) reported that, in 2022, 22 U.S. states had an adult obesity rate of 35% or higher, an increase from 19 states in 2021. As a result, the growing obesity rates are propelling the diabetes treatment devices market.

Leading companies in the diabetes treatment devices market are focusing on developing cutting-edge solutions like hybrid closed-loop insulin pump systems to enhance glycemic control and alleviate the burden of diabetes management for patients. A hybrid closed-loop insulin pump system is an advanced device that adjusts insulin delivery automatically based on readings from continuous glucose monitors (CGMs) while requiring users to manually input mealtime insulin doses. For instance, in March 2022, Medtronic PLC introduced the MiniMed 780G system with SmartGuard technology for managing type 1 diabetes in individuals aged 7 to 80 years. This system automatically adjusts basal insulin levels and provides correction boluses every five minutes to maintain glucose levels within a personalized target range, even compensating for missed meal boluses or incorrect carbohydrate estimates. The system also features Meal Detection technology, a CGM that eliminates the need for fingersticks, and an infusion set that lasts up to seven days, all of which can be controlled via a mobile app.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed sum. This acquisition enables Abbott Laboratories to combine continuous glucose monitoring with smart insulin dosing technology, aiming to deliver more personalized, connected, and accessible diabetes care. Bigfoot Biomedical Inc. is a US-based medical technology company that specializes in developing and providing diabetes treatment devices.

Major players in the diabetes treatment devices market are Johnson And Johnson, Abbott Laboratories, Medtronic plc, Eli Lilly And Company, Novo Nordisk A/S, Becton, Dickinson And Company, Hoffmann-La Roche Ltd., Insulet Corporation, DexCom Inc., Tandem Diabetes Care Inc, Lifescan Inc., Ypsomed Holding AG, Ascensia Diabetes Care Holdings AG, B. Braun Melsungen AG, Beta Bionics Inc, Senseonics Holdings Inc., Bigfoot Biomedical Inc., Medtrum Technologies Inc., Diabeloop SA, Roche Diabetes Care GmbH.

North America was the largest region in the diabetes treatment devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes treatment devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diabetes treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes treatment devices market consists of sales of smart insulin pens, artificial pancreas systems, closed-loop systems, and jet injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The diabetes treatment devices market research report is one of a series of new reports that provides diabetes treatment devices market statistics, including diabetes treatment devices industry global market size, regional shares, competitors with a diabetes treatment devices market share, detailed diabetes treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes treatment devices industry. The diabetes treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetes treatment devices are specialized medical tools designed to help individuals manage and treat diabetes by monitoring blood sugar levels, administering insulin, or addressing related health concerns. These devices play a crucial role in helping patients achieve optimal blood glucose control and prevent complications linked to diabetes.

The primary types of diabetes treatment devices include blood glucose monitoring devices, self-monitoring tools, blood glucose meters, testing strips, lancets, continuous glucose monitoring devices, sensors, transmitters, receivers, and other related equipment. Blood glucose monitoring devices are essential for measuring blood sugar levels, assisting individuals in effectively managing their diabetes. These devices are available through various distribution channels, including hospital pharmacies, retail pharmacies, diabetes clinics, institutional sales, and online pharmacies. They cater to a wide range of users, such as hospitals, homecare settings, diagnostic centers, ambulatory surgery centers, and other healthcare facilities.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.